Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone plus salvage chemotherapy versus salvage chemotherapy alone in first relapsed or refractory acute myeloid leukemia
2018-001467-23Phase 3Terminated
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Feb 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dexamethasone in acute myeloid leukemia (AML) (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Overall survival. Started Feb 2019; status: terminated.
02
Drugs
dexamethasone
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2018-001467-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001467-23.